Among the hits identified in the drug screening, we observed that CUDC-907, a dual-target inhibitor of PI3K and HDAC, effectively suppressed leukemia cell proliferation by more than 90% in both MH and MB cells at nanomolar concentrations (Fig. 2b and Supplementary Fig. 1a). Here, HDAC9 is linked to leukemia.